Shanghai Fosun Pharma plans to sell ex-China rights for two drug candidates in pharma licensing deal– one treating cancer, the other diabetes – to Sellas Clinicals Holding of Switzerland.
Sellas will pay up to $531.4 million in clinical milestones, based on trials in the US and Europe.
The pharma licensing agreement, which has not been finalized, will be between an indirect subsidiary of Fosun, Chongqing Fochon Pharma, and Sellas.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity